"Antigens, CD20" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Unglycosylated phosphoproteins expressed only on B-cells. They are regulators of transmembrane Ca2+ conductance and thought to play a role in B-cell activation and proliferation.
| Descriptor ID |
D018951
|
| MeSH Number(s) |
D23.050.301.264.035.120 D23.050.301.264.051.120 D23.101.100.110.120 D23.101.100.150.120
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antigens, CD20".
- Chemicals and Drugs [D]
- Biological Factors [D23]
- Antigens [D23.050]
- Antigens, Surface [D23.050.301]
- Antigens, Differentiation [D23.050.301.264]
- Antigens, CD [D23.050.301.264.035]
- Antigens, CD20 [D23.050.301.264.035.120]
- Antigens, Differentiation, B-Lymphocyte [D23.050.301.264.051]
- Antigens, CD20 [D23.050.301.264.051.120]
- Biomarkers [D23.101]
- Antigens, Differentiation [D23.101.100]
- Antigens, CD [D23.101.100.110]
- Antigens, CD20 [D23.101.100.110.120]
- Antigens, Differentiation, B-Lymphocyte [D23.101.100.150]
- Antigens, CD20 [D23.101.100.150.120]
Below are MeSH descriptors whose meaning is more specific than "Antigens, CD20".
This graph shows the total number of publications written about "Antigens, CD20" by people in this website by year, and whether "Antigens, CD20" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 3 | 4 |
| 2004 | 1 | 2 | 3 |
| 2005 | 1 | 1 | 2 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 2 | 2 |
| 2009 | 1 | 0 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antigens, CD20" by people in Profiles.
-
Nijjar PS, Masri SC, Tamene A, Kassahun H, Liao K, Valeti U. Benefits and limitations of multimodality imaging in the diagnosis of a primary cardiac lymphoma. Tex Heart Inst J. 2014 Dec; 41(6):657-9.
-
Voo KS, Foglietta M, Percivalle E, Chu F, Nattamai D, Harline M, Lee ST, Bover L, Lin HY, Baladandayuthapani V, Delgado D, Luong A, Davis RE, Kwak LW, Liu YJ, Neelapu SS. Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma. Int J Cancer. 2014 Dec 15; 135(12):2834-46.
-
Rafiq S, Butchar JP, Cheney C, Mo X, Trotta R, Caligiuri M, Jarjoura D, Tridandapani S, Muthusamy N, Byrd JC. Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties. J Immunol. 2013 Mar 15; 190(6):2702-11.
-
Nightingale G. Ofatumumab: a novel anti-CD20 monoclonal antibody for treatment of refractory chronic lymphocytic leukemia. Ann Pharmacother. 2011 Oct; 45(10):1248-55.
-
Xu H, Yan Y, Williams MS, Carey GB, Yang J, Li H, Zhang GX, Rostami A. MS4a4B, a CD20 homologue in T cells, inhibits T cell propagation by modulation of cell cycle. PLoS One. 2010; 5(11):e13780.
-
Menge T, Büdingen HC, Dalakas MC, Kieseier BC, Hartung HP. [Targeting B cells in multiple sclerosis. Current concepts and strategies]. Nervenarzt. 2009 Feb; 80(2):190-8.
-
Sevilla DW, Gong JZ, Goodman BK, Buckley PJ, Rosoff P, Gockerman JP, Lagoo AS. Clinicopathologic findings in high-grade B-cell lymphomas with typical Burkitt morphologic features but lacking the MYC translocation. Am J Clin Pathol. 2007 Dec; 128(6):981-91.
-
Baz R, Fanning S, Kunkel L, Gaballa S, Karam MA, Reed J, Kelly M, Hussein M. Combination of rituximab and oral melphalan and prednisone in newly diagnosed multiple myeloma. Leuk Lymphoma. 2007 Dec; 48(12):2338-44.
-
Magro CM, Seilstad KH, Porcu P, Morrison CD. Primary CD20+CD10+CD8+ T-cell lymphoma of the skin with IgH and TCR beta gene rearrangement. Am J Clin Pathol. 2006 Jul; 126(1):14-22.
-
Rawal YB, Nuovo GJ, Frambach GE, Porcu P, Baiocchi RA, Magro CM. The absence of CD20 messenger RNA in recurrent cutaneous B-cell lymphoma following rituximab therapy. J Cutan Pathol. 2005 Oct; 32(9):616-21.